Paget's disease of bone: Clinical, pathogenetic and therapeutic aspects

Bailliere's Clinical Endocrinology and Metabolism

Volumn 11, Issue 1, 1997, Pages 117-143

  Papapoulos, S E ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bisphosphonates; Bone formation; Bone pain; Bone resorption; Calcitonin; Osteoclasts; Paget's disease; Paramyxoviruses

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; PAMIDRONIC ACID; TILUDRONIC ACID;

AGING; BONE REMODELING; BONE TURNOVER; CLINICAL FEATURE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; PAGET BONE DISEASE; PARAMYXOVIRUS; PREVALENCE; REVIEW;

PARAMYXOVIRIDAE;

EID: 0030818853     PISSN: 0950351X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0950-351X(97)80553-8     Document Type: Article

References (87)

1. Adami S Zamberlan N Adverse effects of bisphosphonates: a comparative review Drug Safety 14 1996 158 170
2. Adami S Mian M Gatti P Effect of two oral doses of alendronate in the treatment of Paget's disease of bone Bone 15 1994 415 417
3. Adamson BB Gallacher SJ Byars J Mineralisation defects with pamidronate therapy for Paget's disease Lancet 342 1993 1459 1460
4. Basle MF Fournier JG Rozenblatt S Measles virus RNA detected in Paget's disease bone tissue by in situ hybridisation Journal of General Virology 67 1986 907 913
5. Bijvoet OLM Jansen A Thyrocalcitonin in Paget's disease Lancet ii 1967 472
6. Bijvoet OLM Vellenga CJLR Harinck HIJ Paget's disease of bone: assessment, therapy and secondary prevention Kleerekoper M Krane SM Clinical Disorders of Bone and Mineral Metabolism 1989 Liebert Copenhagen, Denmark 525 542
7. Bijvoet OLM Papapoulos SE Löwik CWGM Harinck HIJ Manipulation of cell-cell interaction in bone with bisphosphonate in the interpretation of bone and calcium homeostasis in man Cohn DV Calcium Regulation and Bone Metabolism-Basic and Clinical Aspects 9 1987 Excerpta Medica New York 93 104
8. Bijvoet OLM Frijlink WB Jie K APD in Paget's disease of bone Role of mononuclear phagocyte system? Arthritis and Rheumatism 23 1980 1193 1204
9. Blumsohn A Haylor KE Assiri AMA Eastell R Different responses of biochemical markers of bone resorption to bisphosphonate therapy in Paget's disease Clinical Chemistry 41 1995 1592 1598
10. Bockman RS Wilhelm F Siris E A multicenter trial of low dose gallium nitrate in patients with advanced Paget's disease of bone Journal of Clinical Endocrinology and Metabolism 80 1995 595 602
11. Boyce BF Fogelman I Ralson S Focal osteomalacia due to low-dose diphosphate therapy in Paget's disease Lancet i 1984 821 824
12. Brumsen C Bloem RM Papapoulos SE Paget's disease with osteolytic lesions: combining medical and surgical treatments Netherlands Journal of Medicine 40 1992 292 298
13. Cartwright EJ Gordon MT Freemont AJ Paramyxoviruses and Paget's disease Journal of Medical Virology 40 1993 135 141
14. (supplement) Chines A Bekker P Clarke P Hosking D Reduction of bone pain and alkaline phosphatase in patients with severe Paget's disease of bone following treatment with risedronate Journal of Bone and Mineral Research 11 1996 S371
15. Cundy T McAnulty K Wattie D Evidence for secular change in Paget's disease Bone 20 1997 69 71
16. De Vries HR Bijvoet OLM Results of prolonged treatment of Paget's disease of bone with disodium ethane-l-hydroxy-l, l-diphosphonate (EHDP) Netherlands Journal of Medicine 17 1974 281 297
17. Delmas PD Biochemical markers of bone remodelling in osteoporosis Papapoulos SE Lips P Pols HAP Johnston CC Delmas PD Osteoporosis 96 1996 Elsevier Science Amsterdam 191 204
18. (in press) Delmas PD Meunier PJ The management of Paget's disease of bone New England Journal of Medicine 1997
19. Delmas PD Chapuy MC Vignon E Long term effects of dichloromethylene diphosphonate in Paget's disease of bone Journal of Clinical Endocrinology and Metabolism 54 1982 837 844
20. Delmas PD Demiaux B Malaval L Serum bone gla-protein is not a sensitive marker of bone turnover in Paget's disease of bone Calcified Tissue International 38 1986 60 61
21. Delmas P Chapuy MC Edouard C Beneficial effects of aminohexane diphosphonate in patients with Paget's disease of bone resistant to sodium etidronate American Journal of Medicine 83 1987 276 282
22. Delmas PD Gineyts E Bertholin A Immunoassay of pyridinoline crosslink excretion in normal adults and in Paget's disease Journal of Bone and Mineral Research 8 1993 643 648
23. Demulder A Takahashi S Singer FR Abnormalities in osteoclast precursors and marrow accessory cells in Paget's disease Endocrinology 133 1993 1978 1982
24. Evans RA Dunstan CR Hills E Wong SYP Pathological fracture due to severe osteomalacia following low-dose disphosphonate treatment of Paget's disease of bone Australian and New Zealand Journal of Medicine 13 1983 277 279
25. Fenton A Cutteridge DH Kent GN Intravenous aminobisphosphonates in Paget's disease: clinical, biochemical, histomorphometric and radiological responses Clinical Endocrinology 34 1991 197 204
26. Fleisch H Bisphosphonates in Bone Disease: from the Laboratory to the Patient 3rd edn. 1997 Parthenon Publishing Group Amsterdam
27. Foley-Nolan D Daly MJ Williams Pamidronate associated hallucinations Annals of the Rheumatic Diseases 51 1992 927 928
28. Frijlinck WB Te Velde J Bijvoet OLM Heynen G Treatment of Paget's disease of bone with 3-amino-l-hydroxypropylidene-1, 1-bisphosphonate (APD) Lancet i 1979 799 803
29. Garnero P Gineyts E Riou JP Delmas PD Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease Journal of Clinical Endocrinology and Metabolism 79 1994 780 785
30. Geddes AD D'Souza SM Ebetino FH Ibbotson KJ Bisphosphonates: structure-activity relationships and therapeutic implications Heersche JNM Kanis JA Bone and Mineral Research Annual 8 1994 Elsevier Science New York 265 306
31. Gordon MT Anderson DC Sharpe PT Canine distemper virus localised in bone cells of patients with Paget's disease Bone 12 1991 195 201
32. Gray RES Yates AJP Preston CJ Duration of effect of oral diphosphonate therapy in Paget's disease Quarterly Journal of Medicine 245 1987 755 767
33. Hamdy NAT Papapoulos SE Colwell A Urinary collagen crosslink excretion: a better index of bone resorption than hydroxyproline in Paget's disease of bone? Bone and Mineral 22 1993 1 8
34. Hanson DA Weis MAE Bollen A-M A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine Journal of Bone and Mineral Research 7 1992 1251 1258
35. Harinck HIJ Bijvoet OLM Vellenga CJLR Relation between signs and symptoms in Paget's disease of bone Quarterly Journal of Medicine 58 1986 133 151
36. Harinck HIJ Bijvoet OLM Blanksma HJ Dahlinghaus-Nienhuys PJ Efficacious management with aminobisphosphonate (APD) in Paget's disease of bone Clinical Orthopaedics 217 1987 79 98
37. Harinck HIJ Papapoulos SE Blanksma HJ Paget's disease of bone: early and late response to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD) British Medical Journal 295 1987 1301 1305
38. Harvey L Gray T Beneton MNC Ultrastructural features of the osteoclast from Paget's disease of bone in relation to viral aetiology Journal of Clinical Pathology 35 1982 771 779
39. Hoyland JA Freemont AJ Sharpe PT Interleukin-6, IL-6 receptor, and IL-6 nuclear factor gene expression in Paget's disease Journal of Bone and Mineral Research 9 1994 75 80
40. Ishimi Y Miyaura C Jin CH IL-6 is produced by osteoblasts and induces bone resorption Journal of Immunology 145 1990 3297 3303
41. Kanis JA Pathophysiology and Treatment of Paget's Disease of Bone 1991 Dunitz Amsterdam
42. Khan SA McCloskey EV Nakatsuka K Duration of response with oral clodronate in Paget's disease of bone Bone 18 1996 185 190
43. Kukita A Chenu C McManus LM Atypical multinucleated cells formed in long-term marrow cultures from patients with Paget's disease Journal of Clinical Investigation 85 1990 1280 1286
44. Löwik C van der Pluijm G Mechanisms of action of bisphosphonates: studies with bone culture systems Bijvoet OLM Fleisch H Canfield RE Russell RGG Bisphosphonate on Bones 1995 Elsevier London 155 170
45. Löwik CWGM van der Pluijm G Bloys H Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin 6 production by osteogenic cells: a possible role of interleukin 6 in osteoclastogenesis Biochemical and Biophysical Research Communications 162 1989 1546 1552
46. (supplement) McClung MR Tou CKP Goldstein NH Picot C Tiludronate therapy for Paget's disease of bone Bone 17 1995 S493 S496
47. Marcarol V Fraunfelder F Pamidronate disodium and possible ocular adverse drug reaction American Journal of Ophthalmology 118 1994 220 224
48. (supplement) Meunier PJ Vignot E Therapeutic strategy in Paget's disease of bone Bone 17 1995 S489 S491
49. Meunier PJ Salson C Mathieu L Skeletal distribution and biochemical parameters of Paget's disease Clinical Orthopaedics 217 1987 37 44
50. Mills B Singer FR Weiner LP Holst PA Immunohistochemical demonstration of respiratory syncytial virus antigen in Paget's disease of bone Proceedings National Academy of Science USA 78 1981 1209 1221
51. Morales-Piga AA Rey-Rey JS Lorres-González J Frequency and characteristics of familial aggregation of Paget's disease of bone Journal of Bone and Mineral Research 10 1995 663 670
52. Paget J On a form of chronic inflammation of bones (osteitis deformans) Medico-chirurgical Transactions of London 60 1877 37 63
53. Papapoulos SE Pharmacodynamics of bisphosphonates in man: implications for treatment Bijvoet OLM Fleisch H Canfield RE Russell RGG Bisphosphonate on Bones 1995 Elsevier Amsterdam 231 245
54. Papapoulos SE Bisphosphonates: pharmacology and use in the treatment of osteoporosis Marcus R Feldman D Kelsey J Osteoporosis 1996 Academic Press Amsterdam 1209 1233
55. Papapoulos SE Frölich M Prediction of the outcome of treatment of Paget's disease of bone with bisphosphonates from short-term changes in the rate of bone resorption Journal of Clinical Endocrinology and Metabolism 81 1996 3993 3997
56. Papapoulos SE Harinck HSJ Bijvoet OLM Effects of decreasing serum calcium on circulating parathyroid hormone and vitamin D metabolites in normocalcaemic and hypercalcaemic patients treated with APD Bone and Mineral 1 1986 69 78
57. Papapoulos SE Frölich M Mudde AH Serum osteocalcin in Paget's disease of bone: basal concentrations and response to bisphosphonate treatment Journal of Clinical Endocrinology and Metabolism 65 1987 89 94
58. Papapoulos SE Hockman K Löwik CWGM Application of an in vitro model and a clinical protocol in the assessment of the potency of a new bisphosphonate Journal of Bone and Mineral Research 4 1989 775 781
59. Patel S Stone MD Couplana C Hosking DJ Determinants of remission of Paget's disease of bone Journal of Bone and Mineral Research 12 1993 1467 1473
60. van der Pluijm G Löwik CWGM De Groot H Modulation of PTH-stimulated osteoclastic resorption by bisphosphonates in fetal mouse bone explants Journal of Bone and Mineral Research 6 1991 1203 1210
61. Posen S Clifton-Bligh P Wilkinson M Paget's disease of bone and hyperparathyroidism: Coincidence or causal relationship? Calcified Tissue Research 26 1978 107 109
62. Pringle CR Wilkie MI Elliot RM A survey of respiratory syncytial and parainfluenza virus type 3 neutralising and immunoprecipitating antibodies in relation to Paget's disease Journal of Medical Virology 17 1985 377 386
63. Ralston SJ Digioviye FS Gallaher SJ Failure to detect paramyxovirus sequences in Paget's disease of bone using polymerase chain reaction Journal of Bone and Mineral Research 6 1991 1243 1284
64. Rebel A Malkani K Basle M Anomalies nucleaires des ostéoclastes de la maladie osseuse de Paget Nouvelle Presse Medicale 3 1974 1299 1301
65. Rebel A Malkani K Basle M Bregeon C Osteoclast ultrastructure in Paget's disease Calcified Tissue Research 20 1976 187 199
66. Reddy SV Singer FR Roodman GD Bone marrow mononuclear cells from patients with Paget's disease contain measles virus nucleocapsid messenger ribonucleic acid that has mutations in a specific region of the sequence Journal of Clinical Endocrinology and Metabolism 80 1995 2108 2111
67. Reddy SV Singer FR Malette L Roodman GD Detection of measles virus nucleocapsid transcripts in circulating blood cells from patients with Paget disease Journal of Bone and Mineral Research 11 1996 1602 1607
68. Reginster JY Colson F Morlock G Evaluation of the efficacy and safety of oral tiludronate in Paget's disease of bone Arthritis and Rheumatism 35 1992 967 974
69. Reid IR Mills DAJ Wattie DJ Ototoxicity associated with intravenous bisphosphonate administration Calcified Tissue International 56 1995 584 585
70. Rodan GA Fleisch HA Bisphosphonates: mechanism of action Journal of Clinical Investigation 97 1996 2692 2696
71. Roodman GD Biology of the osteoclast in Paget's disease Seminars in Arthritis and Rheumatism 23 1994 235 236
72. Roodman GD Kurihara N Ohsaki Y Interleukin 6: a potential autocrine/paracrine factor in Paget's disease of bone Journal of Clinical Investigation 89 1992 46 52
73. Roux C Listrat V Villette B Long-lasting dermatological lesions after tiludronate therapy Calcified Tissue International 50 1992 378 380
74. Roux C Gennari C Farrerons J Comparitive prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone Arthritis and Rheumatism 6 1995 851 858
75. Ryan WG Two decades of experience in the treatment of Paget's disease of bone with Plicamycin (Mithramycin) Singer FR Wallach S Pagets Disease of Bone: Clinical Assessment, Present and Future Therapy 1991 Elsevier Science New York 176 190
76. Ryan PJ Gibson T Fogelman I Bone scintigraphy following intravenous pamidronate (APD) for Paget's disease of bone Journal of Nuclear Medicine 33 1992 1589 1593
77. Schweitzer DH Zwinderman AH Vermeij Improved treatment of Paget's disease with dimethylaminohydroxypropylidene bisphosphonate Journal of Bone and Mineral Research 8 1993 175 182
78. Schweitzer DH Oostendorp-van de Ruit M van der Pluijm G Interleukin-6 and the acute phase response druing treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate Journal of Bone and Mineral Research 10 1995 956 962
79. Siris ES Paget's disease of bone Journal of Clinical Endocrinology and Metabolism 80 1995 335 338
80. Siris ES Seeking the elusive etiology of Paget disease: a progress report Journal of Bone and Mineral Research 11 1996 1599 1601
81. Siris E Ottman R Flaster E Kelsey JL Familial aggregation of Paget's disease of bone Journal of Bone and Mineral Research 6 1991 495 500
82. Siris ES Canfield RE Jacobs TP Clinical and biochemical effects of EHDP treatment of Paget's disease of bone: patterns of response to initial treatment and to long term therapy Metabolic Bone Diseases and Related Research 5 1981 301 308
83. Siris E Weinstein RS Altman R Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone Journal of Clinical Endocrinology and Metabolism 81 1996 961 967
84. Thiebaud D Jaeger P Gobelet C Single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget's disease of bone American Journal of Medicine 85 1988 207 212
85. Uebelhart D Gineyts E Chapuy MC Delmas PD Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone diseases Bone and Mineral 8 1990 87 96
86. Vellenga CJLR Quantitative bone scintigraphy in the evaluation of Paget's disease of bone Bijvoet OLM Fleisch HA Canfield RE Russel RGG Bisphosphonates on Bones 1995 Elsevier Science Amsterdam 279 291
87. Vellenga CJLR Pauwels EKJ Bijvoet OLM Harinck HIJ Quantitative bone scintigraphy in Paget's disease treated with APD British Journal of Radiology 55 1985 1165 1172